TRIUMPH-2's Phase 3 data on retatrutide in 1,152 T2D patients challenges every assumption sponsors hold about GLP-1 trial ...

The TRIUMPH-2 and SYNCHRONIZE-2 studies show both novel agents to be highly effective, but some questions remain.

An experimental drug helped people with Type 2 diabetes lose more than one-fifth of their body weight in a clinical trial.

Back in Time revisits the history of Torremolinos as the birthplace of rock and roll in Spain through the testimonies of key figures from music and popular culture. Written and directed by Manuel ...

A little more than half a year after opening Logma, the chef-owners invited their closest friends and collaborators for a ...

A drug targeting three hormone pathways also improved several markers of cardiovascular and metabolic health (Artist’s concept). Credit: Stock. Retatrutide could help tackle obe ...

Proposed acquisition would combine QeM's quantum-secure technologies with Plurilock's established cybersecurity revenue base, hundreds of customer relationships, public-sector procurement channels, ...

September 30, 2026) - Quantum eMotion Corp. (NYSE American: QNC) (TSXV: QNC) (FSE: 34Q0) ("QeM" or the "Corporation") is pleased to announce the appointment of a new independent director, Bernard ...

Quantum-focused Montréal firm wants to use Victoria-based counterpart to broaden cybersecurity offerings. Montréal-based Quantum eMotion (QeM) is looking beyond quantum security by acquiring ...

Patent milestone strengthens QeM's intellectual-property portfolio and advances the commercialization of its high-assurance, quantum-resilient cybersecurity platformMontreal, Quebec--(Newsfile Corp. - ...